A PYMNTS Company

US: FTC invigorates pay-for-delay battle

By  |  June 23, 2014

Just days after sources said the European Commission was preparing to issues fines against generic drug makers for anticompetitive practices, reports say authorities in the US are also revamping their efforts against unfair tactics in the pharmaceutical industry.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to reports, the Federal Trade Commission launched new investigations into pay-for-delay agreements made between drug manufacturers, in the wake of a Supreme Court decision last year that armed antitrust law with the legal ability to fight such pacts.

    Pay-for-delay deals allow a brand name drug maker to pay its cheaper, generic rival to keep its competition off the shelf.

    With the Supreme Court ruling, the FTC has launched probes into agreements made between generic and brand name companies; according to filings, the regulator is eyeing Forest Laboratories and Endo International.

    Reports say the investigations could lead to fines and lawsuits.

    Full content: Businessweek

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.